Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

UBROGEPANT vs UMBRALISIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

UBROGEPANT vs UMBRALISIB: Safety Overview

Metric UBROGEPANT UMBRALISIB
Total FAERS Reports 2,531 293
Deaths Reported 49 30
Death Rate 1.9% 10.2%
Hospitalizations 145 97
Average Patient Age 49.2 yrs 69.0 yrs
% Female Patients 83.6% 43.8%
FDA Approval Date Dec 23, 2019 Feb 5, 2021
Manufacturer Allergan, Inc. N/A
Route ORAL N/A
Marketing Status Prescription Discontinued